Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unknown significance (VUS) in BRCA1 and BRCA2 genes-Reference-Cited by-同舟云学术

Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unknown significance (VUS) in BRCA1 and BRCA2 genes

Published:2023-09-19 Issue:6 Volume:92 Page:501-510
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Militello Anna Maria,Orsi Giulia,Cavaliere Alessandro,Niger Monica,Avallone Antonio,Salvatore Lisa,Tortora Giampaolo,Rapposelli Ilario Giovanni,Giordano Guido,Noventa Silvia,Giommoni Elisa,Bozzarelli Silvia,Macchini Marina,Peretti Umberto,Procaccio Letizia,Puccini Alberto,Cascinu Stefano,Montagna Cristina,Milella Michele,Reni Michele^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s00280-023-04585-w.pdf

Reference46 articles.

1. Siegel RL et al (2021) Cancer statistics, 2021. Ca Cancer J Clin 71(1):7–33

2. Wattenberg MM et al (2020) Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation. Br J Cancer 122(3):333–339

3. Pokataev I et al (2020) Efficacy of platinum-based chemotherapy and prognosis of patients with pancreatic cancer with homologous recombination deficiency: comparative analysis of published clinical studies. ESMO open. 5(1):e000578

4. Rosen MN (2021) BRCA mutated pancreatic cancer: a change is coming. World J Gastroenterol 27(17):1943

5. Golan T et al (2014) Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. Br J Cancer 111(6):1132–1138

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A pilot study of chlorambucil in pre-treated metastatic pancreatic adenocarcinoma patients bearing germline BRCA or other DNA damage repair system variants;Pancreatology;2024-09